NCT05420948View on ClinicalTrials.gov

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHead and Neck NeoplasmsHead CancerThroat Carcinoma
Interventions
DRUG

Pembrolizumab

A drug that binds to a protein called programmed cell death 1 (PD-1) to help immune cells kill cancer cells better. Pembrolizumab is used to treat many different types of cancer.

DRUG

Carboplatin

A chemotherapy drug used to treat cancer.

DRUG

Paclitaxel

A chemotherapy drug used to treat cancer.

Trial Locations (1)

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER